5 Undervalued European Stocks Flashing Trend-Reversal Signals Before 2027

European equities have spent much of the past three years trading at a persistent discount to their US peers — and nowhere is that discount deeper than among the continent's fallen small and mid-caps. But 2026 is quietly producing a countertrend: some of the most undervalued stocks in Europe are printing the classic technical signatures that precede durable trend reversals. Bayer, the most prominent example, has already completed one. The question for investors hunting the best stocks to watch into 2027 is which names are next in the sequence — and this guide maps five candidates, each at a different stage of the same journey.

Undervalued European Stocks – Key Takeaways

Stock	Reversal stage	Level to watch	What confirms it
Bayer (BAYN)	Reversal confirmed	€53–56.60 consensus zone	Earnings catching up with the re-rating
Aixtron (AIXA)	Correction in new uptrend	€43–44 (50-day MA)	Reclaim of the 50-day line on the H2 ramp
NAGA Group (N4G)	Base before confirmation	€3.50, then €4.20	Weekly close above the 50-week MA, first higher high
Worldline (WLN)	Balance-sheet repair	First higher low	A confirmed technical bottom
Evotec (EVT)	Still in capitulation	Exhaustion-volume low	Watchlist only — no signal yet

Watch stocks in real time  

How to read a trend reversal: the four-stage checklist

Trend reversals in beaten-down stocks rarely arrive as a single event. They unfold in stages, and each stage has an observable signature on the chart:

• first, a capitulation low on exceptional volume — forced selling exhausting itself;
• second, a base — price stabilizing above the low and printing a first higher low;
• third, the reclaim of a key moving average, typically the 50-week line, which shifts the trend framework;
• fourth, a higher high that confirms the new structure.

Fundamentals decide whether the pattern completes, but the sequence itself is remarkably consistent across markets and decades. For a deeper walkthrough of how valuation and technicals interact, see our Academy lesson on how to identify undervalued stocks.

A note on method: "undervalued" here describes stocks trading far below their multi-year highs and, in most cases, below the published analyst consensus — not a formal valuation model. Prices and levels are as of end of August 2026. The five names below each sit at a different point in the reversal sequence — from a turnaround already confirmed to one still waiting for its first signal.

1. Bayer (XETRA: BAYN) — the completed reversal

Every reversal checklist needs its proof of concept, and in Europe right now that is Bayer. After years pinned down by US glyphosate litigation, the pharmaceutical and crop-science group caught two catalysts in 2026: a June US Supreme Court decision that improved its legal position in key failure-to-warn cases, and the transfer of its US glyphosate operations into a dedicated unit, Ruveon — a structure designed to ring-fence and manage the exposure rather than dispose of it, meaning litigation and settlement-related uncertainty has been reduced, not resolved.

The market treated the combination as decisive anyway: German technical services date the stock's new long-term uptrend from mid-June, and the shares are up around 30% over the summer, reaching a multi-year high above €50 and confirming the trend reversal. A standard 38.2% Fibonacci retracement of the long-term decline points to the €68 area as the first structural reference, with €80 the next technical level.

Past performance is not a reliable indicator of future results. All historical data, including but not limited to returns, volatility, and other performance metrics, should not be construed as a guarantee of future performance.

The analyst consensus has followed rather than led: per finanzen.net's analyst tracker, six of eight covering analysts rate the stock a buy with no sell ratings, and the average 12-month target stands at roughly €56.60 (range €46.00–63.50). That is the anatomy of a completed trend reversal — capitulation, base, reclaim, higher highs, and finally the consensus upgrade cycle.

“Bayer has completed a strong bottom formation and the breakout is now in place. The stock is trading above its 50-day moving average, confirming the improving trend. The next important level is €55. If Bayer can break and hold above €55, the technical picture looks increasingly positive and further upside becomes likely. The reversal is there — now the question is whether the stock can build on it.”

— Frank Walbaum, Market Analyst

Key risk: Glyphosate settlement approval is still pending, and litigation tail risk remains; the pharma pipeline must now justify a re-rated multiple, with much of the good news already priced in.

2. Aixtron (XETRA: AIXA) — the correction inside a new uptrend

Among undervalued tech stocks in Europe, semiconductor equipment maker Aixtron is the study in how violent stage-two-to-stage-three transitions can be. The stock roughly tripled from its 2025 lows as orders for its optoelectronics and gallium-nitride deposition tools accelerated, then surrendered 29% in July alone after a soft first half, falling back to around €38.

Past performance is not a reliable indicator of future results. All historical data, including but not limited to returns, volatility, and other performance metrics, should not be construed as a guarantee of future performance.

The fundamental case survived the correction: management confirmed full-year 2026 guidance of roughly €560 million in revenue (±€30 million) with an EBIT margin of 17–20%, guided the third quarter to €180 million (±€20 million), and returned to profitability in Q2 with a 13% EBIT margin after a loss-making start to the year. The company carries no debt and a substantial cash position. Technically, the reversal framework is intact if the correction holds above the spring base; the signal to watch is a reclaim of the 50-day line near €43-44, where the price action could form a reversal pattern (inverse head-and-shoulders).

“Fundamentally, the recent data remains supportive, while the technical picture is starting to improve. A possible inverse head-and-shoulders pattern is developing. A break above €42.50 would be important, as this level also aligns with the 50-day moving average and the pattern’s neckline. If Aixtron can break and hold above this resistance, the setup could signal a sharp move higher.”

— Frank Walbaum, Market Analyst

Key risk: Full-year guidance requires a steep second-half ramp; order timing in semiconductor capex is inherently lumpy and can defer revenue between quarters.

3. NAGA Group (XETRA: N4G) — the base before confirmation

Technically, the most interesting stage of any reversal is the one German fintech NAGA Group currently occupies: the base that forms after capitulation, before the trend change is confirmed — the point where the risk/reward equation is most clearly defined. The social trading and multi-asset platform operator printed its capitulation low at €1.26 in late February on the heaviest weekly volume in several years, rallied roughly 300% to €6.06 by mid-April, and has since settled into a base around €3 — a retracement that has held well above the pre-rally range, keeping the first higher low of a potential new structure intact.

What separates this base from hope is the fundamental inflection beneath it. In Q1 2026, NAGA reported the first profitable quarter in its history: net profit of €0.5 million, EBITDA of €2.3 million, and an EBITDA margin of 15.8%, up from 6.1% a year earlier. Audited 2025 results came in 12% above preliminary figures, management guides to €68–75 million in revenue and €10–15 million in EBITDA for 2026, and in June the group's European entity, NAGA X Ltd, received authorization as a crypto-asset service provider under the EU's MiCA framework, granted via Cyprus's CySEC and passportable across the EEA — days before the deadline that forced unauthorized providers to retreat from the bloc. Published research targets — house targets from individual firms, not a consensus — range from €9.50 (SMC Research, Speculative Buy, April 2026) to €11.30 (Warburg Research).

Past performance is not a reliable indicator of future results. All historical data, including but not limited to returns, volatility, and other performance metrics, should not be construed as a guarantee of future performance.

The technical picture is clean: a weekly close above €3.50 would reclaim the 50-week moving average; a break of €4.20 would print the first higher high since April and formally confirm the reversal; above that, the April peak at €6.06 is the next reference, with the declining 200-week average near €8.40 marking the long-term ceiling. A bearish close within the pennant pattern (see the Daily chart) suggests a retest of the €2.80–3.00 base support. The full scenario framework — base, bull, and bear cases with probabilities and catalysts — is laid out in the dedicated NAGA Group stock forecast and price prediction.

“Technically, NAGA has been trading in a triangle formation, and the breakout now seems to be taking shape. The supportive trend since mid-June remains intact, which could open the door for further upside if the breakout holds. €3.50 is the key level to watch. A sustained break above this resistance would significantly improve the technical picture.”

— Frank Walbaum, Market Analyst

Key risk: Trading-based revenue is highly sensitive to market volatility, and as a micro-cap with a thin free float, the stock can move 40% in either direction within a quarter.

4. Worldline (Euronext: WLN) — the balance-sheet repair phase

French payments group Worldline shows what the stage before the base looks like: the fundamental repair that must happen while the chart still looks broken. The stock trades near the bottom of its 52-week range even after a reverse share split, and the market greeted broadly encouraging half-year results with a further sell-off — classic behavior for a name where trust, not arithmetic, is the scarce resource.

Past performance is not a reliable indicator of future results. All historical data, including but not limited to returns, volatility, and other performance metrics, should not be construed as a guarantee of future performance.

The arithmetic, though, is moving: per the July half-year report, net debt was cut from €2.2 billion at end-2025 to roughly €1.1 billion, leverage fell below 2.0x EBITDA half a year ahead of target, Merchant Services returned to 2% growth in Q2, and full-year adjusted EBITDA guidance of €630–650 million was confirmed even as revenue guidance was trimmed. Management does not expect the Financial Services division to return to growth before the second half of 2027 — which is precisely why the stock remains cheap, and precisely what a stage-one investor is underwriting.

“Worldline remains a very high-risk turnaround story, which makes it difficult to buy at this stage. The short-term technical picture has improved, with the stock back above its 50-day moving average. Waiting for a confirmed breakout might make more sense than trying to catch the bottom. If trading at all, this is more of a speculative trade than a long-term investment at this point.”

— Frank Walbaum, Market Analyst

Key risk: No confirmed technical bottom; consensus remains skeptical, revenue guidance was cut at the half-year mark, and the recovery timeline extends into 2027.

5. Evotec (XETRA: EVT) — still in capitulation, watchlist only

Hamburg biotech services group Evotec belongs on this list as the control case: a stock trading near its 52-week low and below the published analyst consensus of about €3.80, where the reversal sequence has not yet begun. The shares lost roughly a third of their value in a single month after July's guidance cut — full-year revenue now seen at €570–610 million with adjusted EBITDA of minus €70–105 million.

Past performance is not a reliable indicator of future results. All historical data, including but not limited to returns, volatility, and other performance metrics, should not be construed as a guarantee of future performance.

The seeds of a future turnaround are identifiable: the Horizon restructuring program is shrinking the site network toward ten locations by the end of 2027 with €75 million in targeted savings, and net sales in the core Discovery & Preclinical business grew 28% in the first half — evidence that customers are staying through the turbulence. Analysts do not expect a return to profitability before 2028. But no capitulation-volume low, no base, no higher low: none of the technical preconditions are in place yet.

“Evotec is still a difficult stock to buy fundamentally, but the technical picture is starting to look more interesting. Pharma and biotech stocks can historically see renewed interest towards the later stages of a broader bull market. If that pattern plays out again, the timing could eventually become more supportive for Evotec. For now, the technical setup points to a continuation of the recent trend. The days for a stronger move may still come — but I would rather see the trend confirm itself than try to anticipate the turnaround.”

— Frank Walbaum, Market Analyst

Key risk: Ongoing cash burn during restructuring pressures the balance sheet; a further guidance disappointment would reset the turnaround clock again.

The bottom line

Undervalued stocks become good investments only when a catalyst forces the market to reprice them — and Europe in 2026 is supplying catalysts at an unusual rate: court rulings, regulatory deadlines, restructuring programs, and the first profitable quarters of completed transformations.

Bayer shows the full sequence pays. Aixtron shows it gets retested. NAGA, Worldline, and Evotec show the earlier stages, where the discount is deepest and the checklist matters most. For investors screening the most undervalued stocks in Europe before 2027, the discipline is the same at every stage: define the confirmation level, define the invalidation level, and let the tape — not the story — make the final argument.

Open a live account   Try a demo